All In Biotech

Drug Trial Radar · NCT00908310

Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)

A Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive OMNISCAN (Gadodiamide Injection) for Contrast-enhanced Magnetic Resonance Imaging.

Last checked: Nov 19, 2026Latest source record: Jul 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

213

Actual

Start

May 2009

Primary completion

Jun 2013

Study completion Sep 2013

Sponsor

Lead sponsor
GE HealthcareIndustry
Sponsor type
Industry
Collaborators
i3 Statprobe
First posted
May 25, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This will be an international, multi-center, post-marketing surveillance study in patients with moderate renal insufficiency who are administered gadodiamide, Omniscan, during a MRI. Omniscan will be administered intravenously at the medical discretion of the prescribing physician.

Conditions

  • Chronic Kidney Disease
  • Renal Insufficiency

Interventions

  • OmniscanDrug

    OMNISCAN will be administered intravenously at the medical discretion of the prescribing physician.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Capture of Post-marketing Safety Information in Patients With Moderate Renal Insufficiency Undergoing Routine Contrast-enhanced MRI With Administration of OMNISCAN in Order to Assess the Risk for Developing Nephrogenic Systemic Fibrosis (NSF).Time frame: Greater than or equal to 7 days post contrast administration.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • GE Healthcare

    Princeton, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.